UPDATE:  The FDA announced that it will push back its decision on whether to approve the reversal agent AndexXa to May 4, 2018.  The original review date was set for February 3, 2018, but the FDA wanted to consider additional information it had requested from Portola, the drug's manufacturer. (12/28/17).   Risk of Bleeding … [Read more...]